Delayed onset thrombocytopenia resulting from effects of MDM2 inhibition on platelet progenitors is characteristic of MDM2 inhibitors (Bauer et al., 2021; Gluck et al., 2020; Patnaik et al., 2015). Here, MDM2 is linked to Thrombocytopenia.